The gut microbiome is increasingly implicated in colorectal cancer (CRC) development. A subgroup of patients diagnosed with CRC show high antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG). However, it is unclear whether the association is also present pre-diagnostically. We assessed the association of antibody responses to SGG proteins in pre-diagnostic serum samples with CRC risk in a case-control study nested within a prospective cohort. Prediagnostic serum samples from 485 first incident CRC cases (mean time between blood draw and diagnosis 3.4 years) and 485 matched controls in the European Prospective Investigation into Nutrition and Cancer (EPIC) study were analyzed for antibody responses to 11 SGG proteins using multiplex serology. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable conditional logistic regression models. Antibody positivity for any of the 11 SGG proteins was significantly associated with CRC risk with 56% positive controls compared to 63% positive cases (OR: 1.36, 95% CI: 1.04-1.77). Positivity for two or more proteins of a previously identified SGG 6-marker panel with greater CRC-specificity was also observed among 9% of controls compared to 17% of CRC cases, corresponding to a significantly increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27). In this prospective nested case-control study, we observed a positive association between antibody responses to SGG and CRC development in serum samples taken before evident disease onset. Further work is required to establish the possibly etiological significance of these observations and whether SGG serology may be applicable for CRC risk stratification.
Introduction
Colorectal cancer (CRC) is among the most frequently diagnosed cancers worldwide with an incidence of 746,000 new cases among men and 614,000 new cases among women in 2012. 1 Inflammation is thought to be among the major etiological risk factors for the development of CRC and is a possible mechanism through which bacterial infections might contribute to carcinogenesis. 2 Changes in the local intestinal tissue can compromise the colonic barrier integrity resulting in a "leaky gut." 3 Certain bacteria may opportunistically infect the intestinal tissue and potentially induce an immune response, although they usually act as commensals. 4 An interesting candidate in this respect might be the intestinal commensal Streptococcus gallolyticus subspecies gallolyticus (SGG), formerly known as Streptococcus bovis biotype I. In the 1970s, it was found that infective endocarditis
What's new?
The gut bacterium Streptococcus gallolyticus subspecies gallolyticus (SGG) has been associated with colorectal cancer (CRC), but whether this association exists pre-diagnostically remains unknown. Here the authors performed a serological study in a prospective setting with samples from the European Prospective Investigation into Nutrition and Cancer (EPIC). They demonstrate a positive association of antibody responses to SGG proteins with CRC risk in pre-diagnostic samples, implicating SGG serology as a new marker for risk of developing CRC.
caused by bacteria belonging to the S. bovis complex, [5] [6] [7] and later more specifically by the subspecies SGG, 8 co-occurred with the presence of colorectal adenoma. A systematic review of CRC case series by showed that 60% of S. bovis-infected individuals in the reviewed studies had a concomitant colorectal adenoma/carcinoma and that SGGinfection was specifically responsible for this association compared to other S. bovis subtypes. 9 It is hypothesized that intestinal lesions are the entry port for the commensal SGG to the blood stream enabling the bacterium to turn pathogenic and cause bacteremia or endocarditis. 10 Antibodies against the infecting SGG may serve as markers for the presence of colorectal neoplasia. A significant association between SGG antibody response and presence of CRC has been observed in several studies, but to date these have been exclusively case-control designs with prevalent CRC cases.
11-14
We previously applied multiplex serology, a fluorescent bead-based high-throughput technology allowing serological typing of several antigens in one reaction, 15 to analyze antibody responses to 11 SGG proteins in a German CRC casecontrol study. We showed that positivity to two or more proteins of a SGG 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179) was associated with a 1.8-fold (95% CI: 1.07-3.06) increased risk of CRC (n 5 318) compared to controls (n 5 228). 16 The 6-marker panel demonstrated a higher specificity for CRC risk compared to positivity towards any one of the 11 SGG proteins included in the multiplex serology panel. 16 These previous findings were based on traditional case-control designs where blood samples were obtained post-diagnosis. It is currently unknown whether antibody responses to SGG are associated with CRC development at various time points before diagnosis, that is, whether SGG infection is merely a consequence of the disease or is in some way involved in CRC etiology. 17 In our study, we evaluated whether antibody responses to SGG proteins, as measured by multiplex serology, in prediagnostic serum samples were associated with the risk of CRC, using serum samples of a case-control subset (485 cases and 485 matched controls) of participants of the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
Methods
Study population, case ascertainment and control selection EPIC is a multinational cohort to investigate the relation between diet, lifestyle and environmental factors with cancer incidence. A detailed description of study design has been published elsewhere. 18 Dietary and lifestyle data as well as biological samples, including serum, were collected at enrollment. The blood collection and processing protocols were standardized across the study centers and blood processing and separation was conducted before freezing. Serum samples were stored at the International agency for research on cancer (IARC, Lyon, France) at 21968C. For multiplex serology analyses, serum samples were shipped on dry ice to the German Cancer Research Center, Heidelberg, Germany.
The nested CRC case-control study analyzed here included pre-diagnostic serum samples from 492 incident CRC cases (primary tumors, C18-C20 as by the 10th Revision of the International Statistical Classification of Diseases, Injury and Causes of Death) and 492 matched controls. Controls were selected by incidence density sampling from all cohort members alive and free of cancer at the time of matching. Cases and controls were matched 1:1 by age at blood collection (66 month to 62 years), sex, study center, time of the day at blood collection (62 to 4 hrs interval), fasting status at blood collection (<3/3-6 hrs); among women by menopausal status, and among premenopausal women, by phase of menstrual cycle and hormone replacement therapy use at time of blood collection. After exclusion of seven case-control pairs due to technical errors during detection, a total of 485 first incident CRC cases (colon n 5 432, rectum n 5 53) were identified that had a mean time between blood draw and diagnosis of 3.4 years (range 0.4 to 8.5 years)
SGG multiplex serology
Serum samples were analyzed for antibody responses against SGG in a final sample dilution of 1:1,000 using multiplex serology. The method is described in detail elsewhere. 15, 16 Briefly, 11 SGG antigens (strain UCN34, Table 1 ) were bacterially expressed as recombinant GST-X-tag fusion proteins and each antigen was affinity-purified on a different bead set marked with a distinct internal fluorescent color (SeroMap, Luminex Corp., Austin, TX, USA). These differently loaded bead sets were mixed to form a suspension antigen array for serum presentation. A Luminex xMAP (Luminex Corp., Austin, TX, USA) analyzer identified the bead set and simultaneously quantified bound serum IgA, IgM and IgG antibodies by a reporter fluorescent conjugate, Streptavidin-R-Phycoerythrin. The level of antibody response was given as median fluorescence intensity (MFI) on at least 100 beads per set. Net MFI values were generated by subtraction of bead-background and GST-tag background MFI values.
Due to lack of an appropriate serological gold standard for comparison with our assay, the cut-off definition for SGG antibody positivity was arbitrary, as described elsewhere. 16 The distribution of antibody responses (MFI) to all 11 SGG proteins among controls was skewed towards low MFI, especially when compared to the outer membrane protein (OMP) of Helicobacter pylori, analyzed in the same experimental setting ( Fig. 1) : the upper quartile of antibody responses does not exceed 100 MFI for any of the SGG antigens, whereas
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this antibody level was exceeded by 50% of the control sera to H. pylori OMP. Among controls, we compared the frequency of individuals with the highest antibody responses (upper 10th percentile) to each protein with the frequency of individuals exceeding the same level of antibody response among cases. The technical minimum cut-off was 30 MFI (Table 1) . Overall SGG positivity was defined as samples giving a high response to any of the 11 SGG proteins to allow for individual immune responses and infection with different strains. In a previous case-control study, we showed that refining the algorithm for overall SGG positivity to two or more proteins in a 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179) strengthened the association with CRC. 16 This algorithm was also applied here as a second definition for SGG positivity.
Statistical analyses
Risk factors for SGG positivity among controls were analyzed using Chi-squared-tests. We estimated the association of incident CRC with antibody responses to individual SGG proteins, positivity to any of the 11 SGG proteins, or 2 or more proteins of the 6-marker panel 16 using conditional logistic regression models to compute odds ratios (OR) and 95% confidence intervals (95% CI). A p value below 0.05 was considered statistically significant. Statistical models were first run conditioned on the matching factors, and subsequently with multivariable adjustment for the following variables: level of education attainment, BMI, smoking status and level of alcohol consumption (g/day) at baseline assessment. Missing observations in these variables were included in the model as individual category to save statistical power. The resulting risk estimates did not substantially differ from those calculated without further adjustment (Supporting Information Table S1 ). Sensitivity analyses were carried out excluding cases diagnosed within two years after blood draw to assess the potential for reverse causation. Explorative sub-group analyses were conducted by sex, age at blood draw applying interaction analyses, as well as by anatomical sub-site.
All statistical analyses were performed with SAS version 9.4 (SAS Institute).
Results

Study characteristics and risk factors for SGG positivity
There were no significant differences between cases and controls in any of the baseline characteristics ( Table 2) .
The comparison of SGG positive versus negative control subjects did not identify any major determinants of SGG positivity (Supporting Information Table S2 ). 
Association of antibody responses to SGG with CRC risk
The risk of developing CRC was significantly increased with positivity to any of the 11 SGG proteins Table 3 ). Positivity for two or more proteins of the previously identified 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179) 16 was also significantly associated with increased CRC risk (OR: 2.17, 95% CI: 1.44-3.27) with 9% positive controls compared to 17% positive cases.
To assess the potential impact of reverse causation, we performed a sensitivity analysis excluding those cases diagnosed within 2 years after blood draw and their respective controls ( Table 3 ). The association for positivity to any of the 11 SGG proteins (OR: 1.38, 95% CI: 1.02-1.87) as well as positivity to two or more proteins of the 6-marker panel (OR: 2.07, 95% CI: 1.29-3.31) with CRC risk was generally unaltered. Positivity to individual proteins Gallo0272 (OR: 1.87, 95% CI: 1.15-3.05) and Gallo2178 (OR: 3.28, 95% CI: 1.25-8.57) retained statistical significance while Gallo0748 lost significance but with little change in the magnitude of the risk estimate (OR: 1.40, 95% CI: 0.90-2.18).
Explorative subgroup analyses
Positivity for two or more proteins of the 6-marker panel was associated with only a minor fraction of CRC cases (17%). We assessed whether particular subgroups showed different risk associations for CRC. Analyses stratified by age at blood draw and sex did not reveal any statistically significant difference between the subgroups (Fig. 2a) . Separate analyses by colon or rectal sub-site showed different associations (Fig. 2b) . Positivity to two or more proteins of the 6-marker panel was associated with a 10-fold increased risk of rectal cancer (95% CI: 1.05-95.78) and a much lower, but also statistically significant, near two-fold higher risk for colon cancer (OR: 1.96, 95% CI: 1.28-3.00). However, it is important to note that the number of rectal cancers was small (n 5 53) resulting in wide confidence intervals and imprecision of the risk estimate.
Discussion
In this CRC case-control study nested within the prospective multinational EPIC cohort, we found that antibody responses to SGG proteins, in particular to two or more proteins 1 Conditional logistic regression model with multivariable adjustment for BMI, education, smoking and alcohol intake at baseline. 2 Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179. Figure 2 . OR and 95% CI for antibody responses to two or more proteins of the SGG 6-marker panel in relation to CRC incidence, overall and in separate conditional logistic regression models (a) by sex and age at blood draw; p interaction: p values for interaction analysis of the respective variables with SGG and CRC (b) by tumor site after adjustment for BMI, education, smoking and alcohol status. The arrowhead is applied if the confidence interval exceeded the displayed axis range.
seropositive among a 6-marker panel (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179) were significantly associated with risk of developing CRC. These findings replicate and expand previous findings from two case-control studies with CRC cases from Spain (multicenter case-control study (MCC Spain)) 14 and an independent German study. 16 In MCC Spain, an association of prevalent CRC with antibody responses to SGG protein Gallo2178 alone and Gallo2178 in combination with Gallo2179 was found.
14 In the German case-control study, the SGG multiplex serology panel was extended to the 11 SGG proteins used in this study. Positivity to any of these proteins was associated with prevalent CRC. Seropositivity for at least two proteins from a 6-marker panel subset (Gallo0272, Gallo0748, Gallo1675, Gallo2018, Gallo2178 and Gallo2179) was more specifically associated with CRC (19% SGG positives) compared to controls (11% of SGGpositives). 16 It is currently unknown whether SGG infects colon tissue before or after initiation of tumor development. However, it is hypothesized that the commensal SGG enters the bloodstream through a leaky epithelium, arising due to various environmental exposures, or along the processes of CRC development. 4 This hypothesis is supported by observations showing the presence of SGG already in early colorectal lesions, including polyps and adenoma. 11, 12, 16, 19 Here, we offer the first prospective observational evidence to support early involvement of SGG in colon carcinogenesis by showing that antibody responses to SGG were more frequently present in subjects who later developed CRC even more than two years after blood draw than those who remained disease-free during the same time-frame. The natural history of CRC is characterized by the progressive development of neoplasia of the colon mucosa and can take up to 10-15 years from an initial polyp to tumor diagnosis. Therefore, it is likely that some of the cases in this study already had a precancerous lesion at the time of recruitment into the cohort, but were undiagnosed and likely asymptomatic.
Although we have no data on CRC screening to estimate the numbers with existing polyps, it is likely to be comparable to other European population studies, such as for Germany where the detection rate of non-advanced and advanced adenoma was 22.3% and 9.0%, respectively, among males and 14.9% and 5.2%, respectively, among females above age 55 years. 20 As only a minority of adenomas progress to cancer, a similar proportion of the controls would also be expected to have some form of colorectal adenoma at blood draw that had not progressed to malignant disease by the end of follow-up. Thus, the finding that antibody responses to SGG appear before cancer diagnosis raises the question whether SGG infection is a potential etiological factor in the transition of an adenoma to malignant disease and whether its detection could help stratify the risk for tumor progression from a precancerous lesion. However, we were unable to directly address this question within the limitations of our study. Reports by Abdulamir et al. found proinflammatory cytokine profiles in human CRC tissue positive for SGG DNA and support the hypothesis of an involvement of SGG in tumor progression. 11, 21 A recent study comprehensively showed that SGG promotes proliferation of colon cancer cells in vitro and tumor development in a mouse model overall supporting a role of SGG in colonic tumorigenesis. 22 Our observations will hopefully stimulate further epidemiological studies with CRC screening data and mechanistic investigations of the potential SGG induced transformation of benign polyps to more advanced disease states.
The antigens selected for SGG multiplex serology include proteins predicted to be present at the cell wall of the bacterium or to be secreted. 23, 24 Pilus proteins Gallo2178 and Gallo2179, both included in the 6-marker panel, were previously shown to be potential virulence factors in endocarditis and for infection of colon tumor tissue by mediating attachment to collagen in tissue. 10, 25 Functions of the other proteins have been so far only predicted by sequence comparison to proteins of other bacteria and include enzymatic (Gallo0112A/B, Gallo0748, Gallo0933 and Gallo2018) as well as adhesion functions (Gallo0272, Gallo0577 and Gallo1570). The function of Gallo1675 is unknown. 26 Future studies should focus on this 6-marker panel as it is a stronger marker for CRC risk than being positive to any of the 11 proteins included in the multiplex serology (OR: 2.17 vs. OR: 1.36, respectively).
Stratification by age and sex did not reveal statistically significant differences. However, the small sub-group sample sizes may have limited the analysis. Secondary sub-group analysis by anatomical sub-site suggested a stronger cancer risk association for the rectum versus the colon with SGG antibody responses. This observation is highly interesting and warrants further investigation, but is limited due to small number of rectal cancer cases (n 5 53) included in the present analysis. The disparity between the number of colon and rectal cancer cases analyzed in this study are due to limited availability of biological samples for the required laboratory analyses in this sub-set of EPIC CRC cases.
Key advantages of this study are its prospective setting, multi-center design and the use of a detailed, validated biomarker approach to assess SGG exposures. A main limitation is the small sample size, being based on a subset of CRC cases in the EPIC cohort with available biological samples for the required SGG biomarker analyses. Furthermore, the SGG exposures assessed here reflect levels at recruitment into the cohort upon blood collection and so may not pertain to longer term exposures. An additional potential limitation applicable to all observational studies is the possibility for residual or uncontrolled confounding. Although, the EPIC data have been very well measured and validated, the possibility of residual confounding cannot ever be wholly discounted. Uncontrolled confounding is unlikely because the multivariate adjusted model presented here addressed a large number of potentially important confounding variables. Nevertheless, in the absence of further confirmation of these findings from a larger series of CRC cases from EPIC or from other prospective cohorts, caution in the interpretation of the findings is necessary.
In conclusion, this study provides the first exploration in a prospective setting of the association between SGG infection and risk of CRC development. Our observations indicate a positive association of antibody responses to SGG proteins with CRC risk, taking into account other important confounding factors. SGG infection, possibly acquired through lifestyle exposures leading to colonic epithelial barrier dysfunction, may be an important etiological component of CRC development. Thus, antibody responses to SGG proteins may be indicative for individuals at increased risk for developing CRC.
